0001474064-13-000062.txt : 20130410 0001474064-13-000062.hdr.sgml : 20130410 20130410181845 ACCESSION NUMBER: 0001474064-13-000062 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130409 FILED AS OF DATE: 20130410 DATE AS OF CHANGE: 20130410 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rogus Joseph J CENTRAL INDEX KEY: 0001299691 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 13754639 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE STREET 2: 3RD FLOOR CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2013-04-09 0000890465 NPS PHARMACEUTICALS INC NPSP 0001299691 Rogus Joseph J 550 HILLS DRIVE BEDMINSTER NJ 07921 0 1 0 0 VP, Technical Operations Common Stock 2013-04-09 4 M 0 5175 5.85 A 24547 D Common Stock 2013-04-09 4 M 0 7374 5.71 A 31921 D Common Stock 2013-04-09 4 M 0 25396 5.71 A 57317 D Common Stock 2013-04-09 4 M 0 7195 3.34 A 64512 D Common Stock 2013-04-09 4 M 0 2875 3.34 A 67387 D Common Stock 2013-04-09 4 S 0 48015 11.50 D 19372 D Stock Option 5.85 2013-04-09 4 M 0 5175 0 D 2018-10-15 Common Stock 5175 0 D Stock Option 5.71 2013-04-09 4 M 0 7374 0 D 2019-01-20 Common Stock 7374 0 D Stock Option 5.71 2013-04-09 4 M 0 25396 0 D 2019-01-20 Common Stock 25396 0 D Stock Option 3.34 2013-04-09 4 M 0 7195 0 D 2020-02-19 Common Stock 7195 0 D Stock Option 3.34 2013-04-09 4 M 0 2875 0 D 2020-02-19 Common Stock 2875 0 D The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective December 6, 2012. On October 15, 2008, the Reporting Person received a grant of 5,175 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the date of grant and 2% each month for the next three years. On January 20, 2009, the Reporting Person received a grant of 7,374 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. On January 20, 2009, the Reporting Person received a grant of 25,396 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. On February 19, 2010, the Reporting Person received a grant of 7,195 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On February 17, 2011, the performance criteria for 11,500 of these options had been satisfied because the Issuer's Phase 3 pivotal study of GATTEX (teduglutide) had met the primary efficacy endpoint of reducing parenteral nutrition dependence in patients with adult short bowel syndrome. These 11,500 options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. /s/ Joseph Rogus, by Edward Stratemeier as attorney-in-fact 2013-04-09